Results 111 to 120 of about 54,591 (139)
Predicting BRCA mutation and stratifying targeted therapy response using multimodal learning: a multicenter study. [PDF]
Ann MedLi Y +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Indian Journal of Cancer, 2022
Ovarian cancer (OC) is one of the most lethal gynecological cancers with a 5-year survival rate that ranges from 30% to 40%. Breast cancer genes (BRCA1 and BRCA2) play a key role in maintaining genomic stability. Mutations in BRCA1/2 genes lead to the accumulation of double-strand breaks, resulting in tumorigenesis.
Vineet, Talwar, Amit, Rauthan
openaire +2 more sources
Ovarian cancer (OC) is one of the most lethal gynecological cancers with a 5-year survival rate that ranges from 30% to 40%. Breast cancer genes (BRCA1 and BRCA2) play a key role in maintaining genomic stability. Mutations in BRCA1/2 genes lead to the accumulation of double-strand breaks, resulting in tumorigenesis.
Vineet, Talwar, Amit, Rauthan
openaire +2 more sources
Fertility in BRCA mutation carriers: counseling BRCA-mutated patients on reproductive issues
Hormone Molecular Biology and Clinical Investigation, 2020Abstract Objectives Genetic testing rates for hereditary breast and ovarian cancer (HBOC) have steadily increased during the past decades resulting in a growing population of young and healthy mutation carriers.
Laura Knabben +3 more
openaire +2 more sources
Doubling Down on BRCA -Mutated Cancer
Trends in Cancer, 2017Immunotherapy is changing the landscape of cancer treatment. Nonetheless, not all malignancies respond, possibly due to low mutational load. Recent work in a TP53-/-BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival ...
Andrea E, Wahner Hendrickson +2 more
openaire +2 more sources
BRCA mutations: An Appalachian experience
Journal of Clinical Oncology, 200620111 Background: BRCA1 and 2 mutations are rare in general population and women with these mutations confer a significantly increased risk of invasive breast and ovarian cancer (65% to 85%, and 15% to 65% cumulative lifetime risk, respectively). A few of these are variant mutations also known as Variant of unknown significance (VUS).
M. A. Mirza +4 more
openaire +1 more source
BRCA mutations: is everything said?
Breast Cancer Research and Treatment, 2018Mutations in the BRCA1 and BRCA2 genes constitute a risk factor for breast cancer development. BRCA mutation research has been an active field since the discovery of the genes, and new mutations in both genes are constantly described and classified according to several systems.We intend to provide an overview of the current state of BRCA1 and BRCA2 ...
Eduardo López-Urrutia +7 more
openaire +2 more sources
Progress in BRCA -Mutated Ovarian Cancer
New England Journal of Medicine, 2018The article by Moore et al.1 in this issue of the Journal is the culmination of a long march for olaparib in the treatment of BRCA-mutated high-grade serous ovarian cancer — one that began with its...
David R, Spriggs, Dan L, Longo
openaire +2 more sources